Measuring the antigen levels, the researchers found that stepwise increases in prostate-specific antigen
predicted a 3-44 fold increased risk of prostate cancer and a 2-12 fold increased risk of prostate cancer mortality.
Prevalence of prostate cancer among men with a prostate-specific antigen
level < or = 4.
in serum occurs predominantlyin complex with alpha 1-antichymotrypsin.
Activation of the zymogen form of prostate-specific antigen
by human glandular kallikrein 2.
Using proportions of free to total prostate-specific antigen
to predict the probability of prostate cancer.
Whereas a single marker, such as prostate-specific antigen
, may mislead a physician, simultaneous readings of multiple plasma proteins should be more definitive.
PSA = prostate-specific antigen
; PSADT = prostate-specific antigen
doubling time; HRPC = hormone-refractory prostate cancer
Serum prostate-specific antigen
complexed to a1-antichymotrypsin as an indicator of prostate cancer.
showed that the incidence of prostate cancer was similar in men with a prostate-specific antigen
(PSA) level of 2.
At the Second Stanford Conference on International Standardization of Prostate-Specific Antigen
(1994), Stamey et al.
Presenting the results of a study that included 21 patients whose prostate-specific antigen
(PSA) levels had begun to rise after prostatectomy, Dr.
If the drug similarly thwarts the cancer in men, it would be the first to employ the enzyme, called prostate-specific antigen
(PSA), as anything more than a blood-test indicator of cancer risk.